Huntingdon Life Sciences reported in early May that its revenues and operating profit for the first quarter of 2004 were the highest the company has reached in the last five years.
Revenues for the first quarter were $37.2 million, an increase of 16.7 percent above the company’s revenues in the first quarter of 2003.
HLS president and managing director Brian Cass said in a press release announcing the results,
When we announced our results for 2003 I noted that new business enquiries remained strong and that we were seeing indications of strong order demand in the beginning of the year. I am pleased to report that net new orders in the first quarter were a record for this company, 34% up on the first quarter of 2003 and 29% ahead of the last quarter of 2003. This growth in orders has increased backlog, and helped support the continuing growth in revenues. Toxicology and pharmaceutical chemistry, two of the company’s core competencies have shown strong growth in orders.
Source:
LSR Announces Q1 2004 results. Press Release, Huntingdon Life Sciences, May 6, 2004.